Reduction in the risk of major adverse cardiovascular events with the BET protein inhibitor apabetalone in patients with recent acute coronary syndrome, type 2 diabetes, and moderate to high likelihood of non-alcoholic fatty liver disease.

导出 LinkOut

翻译打印收藏纠错

作者： Peter P,Toth ^[1] ; Gregory G,Schwartz ^[2] ; Stephen J,Nicholls ^[3] ; Aziz,Khan ^[4] ; Michael,Szarek ^[5] ; Henry N,Ginsberg ^[6] ; Jan O,Johansson ^[7] ; Kamyar,Kalantar-Zadeh ^[8] ; Ewelina,Kulikowski ^[5] ; Ken,Lebioda ^[9] ; Norman C W,Wong ^[5] ; Michael,Sweeney ^[5] ; Kausik K,Ray ^[5] ; BETonMACE Investigators ^[5]

作者单位： CGH Medical Center Sterling, Sterling, IL, USA. ^[1] Division of Cardiology, Cicarrone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, MD, USA. ^[2] Division of Cardiology, University of Colorado School of Medicine, Aurora, CO, USA. ^[3] Monash Cardiovascular Research Centre, Monash University, Melbourne, Australia. ^[4] Resverlogix Corp., Calgary, Alberta, Canada. ^[5] CPC Clinical Research and University of Colorado Anschutz Medical Campus, Aurora, CO, USA. ^[6] State University of New York Downstate School of Public Health, Brooklyn, NY, USA. ^[7] Department of Medicine, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA. ^[8] Division of Nephrology and Hypertension, University of California Irvine, Irvine, CA, USA. ^[9] Imperial Centre for Cardiovascular Disease Prevention, Imperial College, London, UK. ^[10]

DOI 10.1016/j.ajpc.2022.100372

PMID 36039183

发布时间 2022-08-31

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览2

American journal of preventive cardiology

2022年11卷

100372页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Reduction in the risk of major adverse cardiovascular events with the BET protein inhibitor apabetalone in patients with recent acute coronary syndrome, type 2 diabetes, and moderate to high likelihood of non-alcoholic fatty liver disease.

American journal of preventive cardiology

相似文献

American journal of preventive cardiology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Reduction in the risk of major adverse cardiovascular events with the BET protein inhibitor apabetalone in patients with recent acute coronary syndrome, type 2 diabetes, and moderate to high likelihood of non-alcoholic fatty liver disease.

American journal of preventive cardiology

相似文献

American journal of preventive cardiology

相关期刊

检索历史清除